Connect Biopharma (CNTB) Competitors $0.98 -0.08 (-7.92%) (As of 05:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CNTB vs. FULC, ACB, LXEO, TNYA, FATE, DMAC, ATAI, ZNTL, ACRV, and MOLNShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Lexeo Therapeutics (LXEO), Tenaya Therapeutics (TNYA), Fate Therapeutics (FATE), DiaMedica Therapeutics (DMAC), Atai Life Sciences (ATAI), Zentalis Pharmaceuticals (ZNTL), Acrivon Therapeutics (ACRV), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Fulcrum Therapeutics Aurora Cannabis Lexeo Therapeutics Tenaya Therapeutics Fate Therapeutics DiaMedica Therapeutics Atai Life Sciences Zentalis Pharmaceuticals Acrivon Therapeutics Molecular Partners Connect Biopharma (NASDAQ:CNTB) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Does the MarketBeat Community prefer CNTB or FULC? Fulcrum Therapeutics received 80 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 72.00% of users gave Connect Biopharma an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformConnect BiopharmaOutperform Votes1872.00% Underperform Votes728.00% Fulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Which has more volatility and risk, CNTB or FULC? Connect Biopharma has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Is CNTB or FULC more profitable? Connect Biopharma's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Connect BiopharmaN/A N/A N/A Fulcrum Therapeutics N/A -7.31%-6.74% Do institutionals and insiders believe in CNTB or FULC? 58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer CNTB or FULC? Connect Biopharma presently has a consensus target price of $8.00, suggesting a potential upside of 719.59%. Fulcrum Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 120.65%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Connect Biopharma is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media refer more to CNTB or FULC? In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Fulcrum Therapeutics and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.44 beat Fulcrum Therapeutics' score of 0.80 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, CNTB or FULC? Connect Biopharma has higher earnings, but lower revenue than Fulcrum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConnect Biopharma$24.12M2.24-$59.50MN/AN/AFulcrum Therapeutics$80.87M2.82-$97.33M-$0.31-13.65 SummaryConnect Biopharma beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.93M$6.72B$5.04B$8.97BDividend YieldN/A3.07%4.81%4.06%P/E RatioN/A10.40133.0816.93Price / Sales2.24187.581,120.44116.20Price / CashN/A57.1640.6337.95Price / Book0.535.194.754.71Net Income-$59.50M$151.85M$118.34M$225.20M7 Day Performance-20.64%-7.93%11.87%-3.77%1 Month Performance-3.36%-1.49%11.93%4.45%1 Year Performance12.12%12.16%31.39%18.66% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.4498 of 5 stars$0.98-7.9%$8.00+719.6%+12.3%$53.93M$24.12M0.00110Short Interest ↓Gap UpFULCFulcrum Therapeutics2.1857 of 5 stars$4.42+11.6%$9.33+111.2%-15.8%$238.41M$80.87M-13.68100Positive NewsACBAurora Cannabis0.3153 of 5 stars$4.29-0.5%N/A-6.9%$235.26M$200.35M-5.671,073LXEOLexeo Therapeutics3.0201 of 5 stars$7.08+2.9%$23.80+236.2%-44.4%$234.11M$650,000.00-2.1858Positive NewsTNYATenaya Therapeutics3.9148 of 5 stars$2.88+4.7%$17.33+501.9%-32.2%$228.15MN/A-1.91110Analyst ForecastNews CoverageFATEFate Therapeutics3.6449 of 5 stars$2.00+9.3%$6.75+237.5%-37.7%$227.79M$13.45M-1.22550Short Interest ↑DMACDiaMedica Therapeutics2.9218 of 5 stars$5.31-1.3%$7.00+31.8%+89.1%$227.06MN/A-9.6120Short Interest ↓News CoveragePositive NewsATAIAtai Life Sciences2.1405 of 5 stars$1.33-2.2%$9.00+576.7%+4.8%$223.18M$331,000.00-1.6883ZNTLZentalis Pharmaceuticals2.5209 of 5 stars$3.10+0.3%$10.00+222.6%-78.7%$220.91MN/A-1.24160ACRVAcrivon Therapeutics1.2653 of 5 stars$7.00-0.8%$23.67+238.1%+57.1%$217.95MN/A-2.6158Gap DownMOLNMolecular Partners0.697 of 5 stars$5.35-1.5%N/A+19.9%$215.80M$6.00M-2.53180News CoveragePositive News Related Companies and Tools Related Companies FULC Competitors ACB Competitors LXEO Competitors TNYA Competitors FATE Competitors DMAC Competitors ATAI Competitors ZNTL Competitors ACRV Competitors MOLN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNTB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTB Stock Alerts